2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.09A.01 Oligoprogression after Local Ablative Treatment for Oligometastatic Non-Small Cell Lung Cancer

Pdf Summary

This study, conducted by Nina Steinmann and colleagues from the University Hospital of Zurich, examines the outcomes of patients with oligometastatic non-small cell lung cancer (NSCLC) who developed oligoprogression after local ablative treatment (LAT). Oligometastatic NSCLC is characterized by a limited number of distant metastases and is diagnosed in 25-50% of stage IV NSCLC patients. Oligoprogression is the progression of cancer at a limited number of sites, which remains a challenge even with LAT integrated into treatment.<br /><br />Methods involved a retrospective analysis of patients with oligometastatic NSCLC who underwent LAT, including anatomical lung resection, from 2009 to 2023. The analysis was based on patient data maintained by the University Hospital of Zurich’s Thoracic Surgery Department.<br /><br />Results showed that among the study cohort, oligoprogression was the most frequent pattern of relapse post-LAT. The median latency before oligoprogression was 24 months, whereas polyprogression occurred after a median of 8 months. EGFR and KRAS mutations were more prevalent in oligoprogression cases compared to those without progression. Survival analyses demonstrated that patients with oligoprogression had a significantly longer overall survival following the initial diagnosis of metastases compared to those with polyprogression. However, there was no significant survival difference between non-progressive and oligoprogressive patients.<br /><br />The study concludes that oligoprogression is a common relapse pattern but is not necessarily a survival-limiting event in oligometastatic NSCLC patients after LAT. LAT provides robust long-term survival benefits, yet additional studies are needed to unravel the clinicopathological and molecular factors influencing oligoprogression. The findings underscore the importance of LAT and highlight the need for further research to enhance treatment strategies for oligoprogressive NSCLC.

Asset Subtitle

Nina Steinmann

Meta Tag

Speaker Nina Steinmann

Topic Metastatic Non-small Cell Lung Cancer – Local Therapies

Keywords

oligometastatic NSCLC

oligoprogression

local ablative treatment

EGFR mutations

KRAS mutations

overall survival

anatomical lung resection

University Hospital of Zurich

thoracic surgery

retrospective analysis